

**REMARKS**

**STATUS OF THE CLAIMS:**

Claims 1 to 20 are cancelled.

Claims 23 and 27 have been amended.

Claims 21 to 36 are pending.

Claim 23 was amended to correct a typographical error by deleting the "of " term after the "comprises" term and to place this claim in better condition for issuance.. Applicants right to equivalents of Claim 23 is reserved. No new matter has been added.

Claim 27 was amended to delete the "sequence" term after the "vector" term to place this claim in better condition for issuance. Applicants right to equivalents of Claim 27 is reserved. No new matter has been added.


It is respectfully requested that the amendment(s) presented herein be considered and entered prior to issuance of a patent corresponding to the present application.

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-3575

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: March 23, 2006